Press Releases

12.01.2016

IBM and Pfizer to Accelerate Immuno-oncology Research with Watson for Drug Discovery

12.01.2016

LYRICA® (pregabalin) Phase 3 Trial in Pediatric Epilepsy Meets Primary Endpoint

11.30.2016

Pfizer Announces Positive Top-Line Results from the Pivotal Comparative REFLECTIONS B3271002 Study for PF-05280014, a Potential Biosimilar to Herceptin®1 (trastuzumab)

11.29.2016

FDA Accepts the Biologics License Application for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma for Priority Review

11.21.2016

Anthony J. Maddaluna, Executive Vice President and President of Pfizer Global Supply to Retire

11.21.2016

Pfizer Announces Expiration And Results Of Tender Offer For Any And All Of Its 6.200% Senior Notes Due March 15, 2019

11.18.2016

Pfizer Announces Pricing of Tender Offer for Any and All of its 6.200% Senior Notes Due March 15, 2019

11.16.2016

PALOMA-2 Phase 3 Study Published In The New England Journal Of Medicine Demonstrates Clinical Benefit Of Pfizer’s IBRANCE® (palbociclib) In First-Line ER+, HER2- Metastatic Breast Cancer

11.15.2016

Pfizer Announces Results from Phase 3 OPAL Clinical Development Program Investigating XELJANZ® (Tofacitinib Citrate) for Psoriatic Arthritis

11.14.2016

Pfizer Prices $6,000,000,000 Debt Offering

11.14.2016

Pfizer Announces Tender Offer for Any and All of its 6.200% Senior Notes Due March 15, 2019

11.14.2016

Pfizer to Collaborate with National Cancer Institute to Study Three Immunotherapy Agents Targeting Multiple Cancers